Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse.

[1]  A. Hasselblatt,et al.  Dual action of clonidine on insulin release: suppression, but stimulation when α2-adrenoceptors are blocked , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  T. Nakaki,et al.  α2-Adrenoceptors modulating insulin release from isolated pancreatic islets , 1980, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  N. Morgan,et al.  Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. , 2001, Diabetes.

[4]  P. Flatt,et al.  Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14r and RX801080. , 2000, Pharmacological research.

[5]  M. Shih,et al.  Effect of acute and sub-chronic administration of the imidazoline compound S 22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice. , 2000, General pharmacology.

[6]  F. Ashcroft,et al.  In vitro mechanism of action on insulin release of S‐22068, a new putative antidiabetic compound , 1999, British journal of pharmacology.

[7]  M. Shih,et al.  A simple acute in vivo comparative test for sensitivity to insulin in the mouse. , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  N. Morgan,et al.  Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. , 1999, European journal of pharmacology.

[9]  C. A. Ramsden,et al.  Imidazolines and Pancreatic Hormone Secretion a , 1999, Annals of the New York Academy of Sciences.

[10]  H. Bönisch,et al.  Presynaptic Imidazoline Receptors: New Developments in Characterization and Classification a , 1999, Annals of the New York Academy of Sciences.

[11]  M. P. Dillon,et al.  'Seeing through a glass darkly': casting light on imidazoline 'I' sites. , 1998, Trends in pharmacological sciences.

[12]  C. A. Ramsden,et al.  Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. , 1998, European journal of pharmacology.

[13]  B. Guardiola-Lemaitre,et al.  Potent antihyperglycaemic property of a new imidazoline derivative S‐22068 (PMS 847) in a rat model of NIDDM , 1998, British journal of pharmacology.

[14]  N. Morgan,et al.  Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  F. Ashcroft,et al.  Phentolamine block of KATP channels is mediated by Kir6.2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. A. Ramsden,et al.  Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors. , 1997, European journal of pharmacology.

[17]  G. Bertrand,et al.  Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. , 1997, European journal of pharmacology.

[18]  R. Markus,et al.  Are imidazoline receptors involved in sympathetic neurotransmission in rat vas deferens? , 1996, General pharmacology.

[19]  P. Renard,et al.  Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  N. Morgan,et al.  The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1‐ and I2‐sites , 1994, British journal of pharmacology.

[21]  N. Morgan,et al.  Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non‐adrenoceptor idazoxan binding sites , 1993, British journal of pharmacology.

[22]  N. Morgan,et al.  Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. , 1993, European journal of pharmacology.

[23]  A. Roach,et al.  Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. , 1992, European journal of pharmacology.

[24]  N. Morgan,et al.  The α2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells , 1991 .

[25]  U. Panten,et al.  Effects of α‐adrenoceptor antagonists on clonidine‐induced inhibition of insulin secretion by isolated pancreatic islets , 1983 .

[26]  F. Leslie,et al.  EFFECT OF MORPHINE ON ADRENERGIC TRANSMISSION IN THE MOUSE VAS DEFERENS. ASSESSMENT OF AGONIST AND ANTAGONIST POTENCIES OF NARCOTIC ANALGESICS , 1975, British journal of pharmacology.